Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Scandic in connection with its rights issue and the agreement on new credit facilities
Mandate

Vinge has advised Scandic in connection with its rights issue and the agreement on new credit facilities

July 15, 2020 Banking and Finance Capital Markets and Public M&A

Vinge has advised Scandic Hotels Group AB (publ) on a fully underwritten rights issue, which will provide Scandic with issue proceeds amounting up to approximately SEK 1,765 million before deduction of transaction costs, and on the agreement of new credit facilities amounting to SEK 1,400 million.

The new shares are expected to be admitted to trading on Nasdaq Stockholm around 29 June 2020.

With 53,000 hotel rooms in operation at 268 hotels in about 130 locations, Scandic is the leading hotel company in the Nordic region. Most of Scandic’s hotels are operated under the fully-owned Scandic brand, which is the best-known hotel brand in the Nordics.

Scandic is listed on Nasdaq Stockholm, Mid cap.

Vinge’s team primarily consisted of Jesper Schönbeck, David Andersson, Amanda Knutsson, William Kåge, Anders Sundin Lundberg, Eléonore Friberg (Capital markets), Louise Brorsson Salomon, Thomas Sjöberg, Robert Wikholm, Linn Adelwald, Ludvig Wettergren and Elias Lundin (Banking and Finance).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025